KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $14.8 million.

  • Castle Biosciences' Capital Expenditures rose 13258.07% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.4 million, marking a year-over-year increase of 4827.31%. This contributed to the annual value of $28.3 million for FY2024, which is 10795.83% up from last year.
  • As of Q3 2025, Castle Biosciences' Capital Expenditures stood at $14.8 million, which was up 13258.07% from $9.3 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Capital Expenditures high stood at $32.4 million for Q2 2021, and its period low was -$29.7 million during Q4 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $3.9 million (2023), whereas its average is $4.4 million.
  • Over the last 5 years, Castle Biosciences' Capital Expenditures had its largest YoY gain of 174703.87% in 2021, and its largest YoY loss of 514261.46% in 2021.
  • Castle Biosciences' Capital Expenditures (Quarter) stood at -$29.7 million in 2021, then soared by 106.02% to $1.8 million in 2022, then soared by 112.26% to $3.8 million in 2023, then skyrocketed by 99.5% to $7.6 million in 2024, then surged by 96.04% to $14.8 million in 2025.
  • Its Capital Expenditures stands at $14.8 million for Q3 2025, versus $9.3 million for Q2 2025 and $4.7 million for Q1 2025.